Literature DB >> 2024958

Association with prior fluoroquinolone therapy of widespread ciprofloxacin resistance among gram-negative isolates in a Veterans Affairs medical center.

R R Muder1, C Brennen, A M Goetz, M M Wagener, J D Rihs.   

Abstract

We performed a case-control study of risk factors for the acquisition of ciprofloxacin-resistant gram-negative isolates in a Veterans Affairs medical center. Sixty-five patients with resistant isolates and 50 control patients were identified. Prior fluoroquinolone use was significantly more frequent among patients with resistant isolates than it was among controls (58 versus 20%; P = 0.0001). The association with prior quinolone use was stronger in the long-term-care division (81 versus 32%; P = 0.0005) than it was in the acute-care division (29 versus 0%; P = 0.015). On multivariate analysis, prior receipt of a fluoroquinolone was the single most significant risk factor for isolation of a ciprofloxacin-resistant gram-negative organism (P = 0.0001).

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2024958      PMCID: PMC244987          DOI: 10.1128/AAC.35.2.256

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  16 in total

1.  High rate of methicillin resistance of Staphylococcus aureus isolated from hospitalized nursing home patients.

Authors:  C C Hsu; C P Macaluso; L Special; R H Hubble
Journal:  Arch Intern Med       Date:  1988-03

2.  Antibiotic-resistant flora in nursing home patients admitted to the hospital.

Authors:  R P Gaynes; R A Weinstein; W Chamberlin; S A Kabins
Journal:  Arch Intern Med       Date:  1985-10

3.  Emergence of resistance to beta-lactams, aminoglycosides, and quinolones during combination therapy for infection due to Serratia marcescens.

Authors:  C C Sanders; C Watanakunakorn
Journal:  J Infect Dis       Date:  1986-03       Impact factor: 5.226

4.  Analysis of acquired ciprofloxacin resistance in a clinical strain of Pseudomonas aeruginosa.

Authors:  B L Masecar; R A Celesk; N J Robillard
Journal:  Antimicrob Agents Chemother       Date:  1990-02       Impact factor: 5.191

5.  CDC definitions for nosocomial infections, 1988.

Authors:  J S Garner; W R Jarvis; T G Emori; T C Horan; J M Hughes
Journal:  Am J Infect Control       Date:  1988-06       Impact factor: 2.918

6.  Infections among patients in nursing homes: policies, prevalence, problems.

Authors:  R A Garibaldi; S Brodine; S Matsumiya
Journal:  N Engl J Med       Date:  1981-09-24       Impact factor: 91.245

7.  High-level aminoglycoside-resistant enterococci. Colonization of nursing home and acute care hospital patients.

Authors:  M J Zervos; M S Terpenning; D R Schaberg; P M Therasse; S V Medendorp; C A Kauffman
Journal:  Arch Intern Med       Date:  1987-09

8.  A prospective study of nosocomial infections in a chronic care facility.

Authors:  B F Farber; C Brennen; A J Puntereri; J P Brody
Journal:  J Am Geriatr Soc       Date:  1984-07       Impact factor: 5.562

9.  Genetic and physiological characterization of ciprofloxacin resistance in Pseudomonas aeruginosa PAO.

Authors:  N J Robillard; A L Scarpa
Journal:  Antimicrob Agents Chemother       Date:  1988-04       Impact factor: 5.191

10.  Infection control programs in twelve North Carolina extended care facilities.

Authors:  L E Price; F A Sarubbi; W A Rutala
Journal:  Infect Control       Date:  1985-11
View more
  38 in total

1.  Increasing resistance of enterococci to ciprofloxacin.

Authors:  D R Schaberg; W I Dillon; M S Terpenning; K A Robinson; S F Bradley; C A Kauffman
Journal:  Antimicrob Agents Chemother       Date:  1992-11       Impact factor: 5.191

2.  Effect of a multifaceted intervention on number of antimicrobial prescriptions for suspected urinary tract infections in residents of nursing homes: cluster randomised controlled trial.

Authors:  Mark Loeb; Kevin Brazil; Lynne Lohfeld; Allison McGeer; Andrew Simor; Kurt Stevenson; Dick Zoutman; Stephanie Smith; Xiwu Liu; Stephen D Walter
Journal:  BMJ       Date:  2005-09-08

3.  Impact of a fluoroquinolone formulary change on acquisition of quinolone-resistant gram-negative bacilli.

Authors:  B N Hota; S Pur; L Phillips; R A Weinstein; J Segreti
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2005-06       Impact factor: 3.267

4.  Using interrupted time series analysis to assess associations of fluoroquinolone formulary changes with susceptibility of gram-negative pathogens and isolation rates of methicillin-resistant Staphylococcus aureus.

Authors:  John A Bosso; Patrick D Mauldin
Journal:  Antimicrob Agents Chemother       Date:  2006-06       Impact factor: 5.191

Review 5.  The use of quinolones in developing countries.

Authors:  E Rodríguez-Noriega; R Morfin-Otero; S Esparza-Ahumada
Journal:  Drugs       Date:  1993       Impact factor: 9.546

6.  Emergence and infectious complications of ciprofloxacin-resistant Escherichia coli in haematological cancer patients.

Authors:  M G van Kraaij; A W Dekker; E Peters; A Fluit; L F Verdonck; M Rozenberg-Arska
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1998-08       Impact factor: 3.267

Review 7.  Antimicrobial resistance patterns in long term geriatric care. Implications for drug therapy.

Authors:  C A Mao; E L Siegler; E Abrutyn
Journal:  Drugs Aging       Date:  1996-03       Impact factor: 3.923

8.  Role of protein D2 and lipopolysaccharide in diffusion of quinolones through the outer membrane of Pseudomonas aeruginosa.

Authors:  M Michéa-Hamzehpour; Y X Furet; J C Pechère
Journal:  Antimicrob Agents Chemother       Date:  1991-10       Impact factor: 5.191

9.  Emergence of fluoroquinolone-resistant Escherichia coli at a cancer center.

Authors:  W V Kern; E Andriof; M Oethinger; P Kern; J Hacker; R Marre
Journal:  Antimicrob Agents Chemother       Date:  1994-04       Impact factor: 5.191

10.  Ciprofloxacin-induced, low-level resistance to structurally unrelated antibiotics in Pseudomonas aeruginosa and methicillin-resistant Staphylococcus aureus.

Authors:  J Fung-Tomc; B Kolek; D P Bonner
Journal:  Antimicrob Agents Chemother       Date:  1993-06       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.